Kverneland AH - Search Results

1

Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma.

Kverneland AH, Thorsen SU, Granhøj JS, Hansen FS, Konge M, Ellebæk E, Donia M, Svane IM. Kverneland AH, et al. Immunooncol Technol. 2023 Aug 24;20:100396. doi: 10.1016/j.iotech.2023.100396. eCollection 2023 Dec. Immunooncol Technol. 2023. PMID: 37810199 Free PMC article.

2

Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study.

Streitz M, Miloud T, Kapinsky M, Reed MR, Magari R, Geissler EK, Hutchinson JA, Vogt K, Schlickeiser S, Kverneland AH, Meisel C, Volk HD, Sawitzki B. Streitz M, et al. Among authors: kverneland ah. Transplant Res. 2013 Oct 25;2(1):17. doi: 10.1186/2047-1440-2-17. Transplant Res. 2013. PMID: 24160259 Free PMC article.

3

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab.

Kverneland AH, Enevold C, Donia M, Bastholt L, Svane IM, Nielsen CH. Kverneland AH, et al. Oncoimmunology. 2018 Feb 1;7(5):e1424674. doi: 10.1080/2162402X.2018.1424674. eCollection 2018. Oncoimmunology. 2018. PMID: 29721387 Free PMC article.

4

CTLA-4 blockade boosts the expansion of tumor-reactive CD8⁺ tumor-infiltrating lymphocytes in ovarian cancer.

Friese C, Harbst K, Borch TH, Westergaard MCW, Pedersen M, Kverneland A, Jönsson G, Donia M, Svane IM, Met Ö. Friese C, et al. Sci Rep. 2020 Mar 3;10(1):3914. doi: 10.1038/s41598-020-60738-4. Sci Rep. 2020. PMID: 32127601 Free PMC article.

5

Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer.

Kverneland AH, Pedersen M, Westergaard MCW, Nielsen M, Borch TH, Olsen LR, Aasbjerg G, Santegoets SJ, van der Burg SH, Milne K, Nelson BH, Met Ö, Donia M, Svane IM. Kverneland AH, et al. Oncotarget. 2020 Jun 2;11(22):2092-2105. doi: 10.18632/oncotarget.27604. eCollection 2020 Jun 2. Oncotarget. 2020. PMID: 32547707 Free PMC article.

6

Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibition.

Kverneland AH, Borch TH, Granhøj J, Sengeløv H, Donia M, Svane IM. Kverneland AH, et al. Cytotherapy. 2021 Aug;23(8):724-729. doi: 10.1016/j.jcyt.2021.03.003. Epub 2021 Apr 28. Cytotherapy. 2021. PMID: 33933372

7

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma.

Borch TH, Harbst K, Rana AH, Andersen R, Martinenaite E, Kongsted P, Pedersen M, Nielsen M, Kjeldsen JW, Kverneland AH, Lauss M, Hölmich LR, Hendel H, Met Ö, Jönsson G, Donia M, Svane IM. Borch TH, et al. Among authors: kverneland ah. J Immunother Cancer. 2021 Jul;9(7):e002703. doi: 10.1136/jitc-2021-002703. J Immunother Cancer. 2021. PMID: 34210820 Free PMC article.

8

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.

Kverneland AH, Chamberlain CA, Borch TH, Nielsen M, Mørk SK, Kjeldsen JW, Lorentzen CL, Jørgensen LP, Riis LB, Yde CW, Met Ö, Donia M, Svane IM. Kverneland AH, et al. J Immunother Cancer. 2021 Oct;9(10):e003499. doi: 10.1136/jitc-2021-003499. J Immunother Cancer. 2021. PMID: 34607899 Free PMC article.

9

Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens.

Draghi A, Chamberlain CA, Khan S, Papp K, Lauss M, Soraggi S, Radic HD, Presti M, Harbst K, Gokuldass A, Kverneland A, Nielsen M, Westergaard MCW, Andersen MH, Csabai I, Jönsson G, Szallasi Z, Svane IM, Donia M. Draghi A, et al. Front Immunol. 2021 Oct 11;12:705422. doi: 10.3389/fimmu.2021.705422. eCollection 2021. Front Immunol. 2021. PMID: 34707600 Free PMC article.

10

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy.

Chamberlain CA, Bennett EP, Kverneland AH, Svane IM, Donia M, Met Ö. Chamberlain CA, et al. Among authors: kverneland ah. Mol Ther Oncolytics. 2022 Jan 10;24:417-428. doi: 10.1016/j.omto.2022.01.004. eCollection 2022 Mar 17. Mol Ther Oncolytics. 2022. PMID: 35141398 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters